S2G6T-3

S2G6T-3 is a topical investigational drug that was developed by Sol-Gel Technologies for the treatment of infectious diseases, specifically skin infections such as tinea pedis (athlete’s foot). It reached Phase 2 clinical trials in the United States for this indication but development has since been discontinued. The precise mechanism of action and active ingredients are not publicly disclosed, but it was evaluated as part of a combination therapy approach targeting symptomatic inflammatory interdigital tinea pedis. No further details on its pharmacological class or molecular targets are available from public sources[1].